Diaceutics (LSE:DXRX) Research & Development: £0.00 Mil (TTM As of Dec. 2025)


LSE:DXRX Diaceutics PLC LSE:DXRX
92 GF Score
Price £1.45
GF Value £1.91
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Diaceutics Research & Development?

Diaceutics LSE:DXRX 92 Research & Development is £0.00 Mil as of Dec. 2025. GuruFocus rates LSE:DXRX with a GF Score™ of 92/100 and a GF Value™ of £1.91 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Diaceutics's Research & Development for the six months ended in Dec. 2025 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00 Mil.

Diaceutics  (LSE:DXRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Diaceutics Research & Development Related Terms

Diaceutics Research & Development Historical Data

* Premium members only.

The historical data trend for Diaceutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics Research & Development Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:DXRX
92GF Score
Diaceutics PLC LSE:DXRX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diaceutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
Diaceutics (LSE:DXRX) has a Research & Development of £0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Diaceutics and its competitors.
Is Diaceutics' Research & Development too high?
Diaceutics' current Research & Development is £0.00 Mil. Overall, Diaceutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Research & Development compare to VEEV and BTSG?
Diaceutics' Research & Development of £0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Diaceutics and its competitors. Diaceutics's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (LSE:DXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is £1.91, compared to a current price of £1.45 — trading 24.1% below its estimated fair value. The current Research & Development is £0.00 Mil. Diaceutics' overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Diaceutics (LSE:DXRX), the current Research & Development is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diaceutics (LSE:DXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of £1.45 is trading 24.1% below its estimated GF Value™ of £1.91. GuruFocus considers Diaceutics to be Modestly Undervalued.

Key valuation signals for LSE:DXRX:

  • Research & Development: £0.00 Mil
  • GF Value™: £1.91 vs. price of £1.45 (24.1% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the LSE:DXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diaceutics Business Description

Other Exchanges DIUXF:USA7DC:Germany
Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
92GF Score

Get the complete analysis for LSE:DXRX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.45
Price
£1.91
GF Value